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Abstract 
Studies have shown that moderate alcohol consumption is strongly associated with reduced 
reporting of chronic widespread pain (CWP). The study designs used however are prone to 
confounding and are not able to establish the direction of causality. The current study 
overcomes these problems by using the Mendelian randomisation design to determine the 
effect of alcohol consumption on the likelihood of reporting CWP. The UK Biobank recruited 
500,000 participants aged between 40 and 69 years. Data collected included questions on 
chronic pain and alcohol consumption, and biological samples providing genotypic 
information. Alcohol consumption was categorised as ‘weekly consumption’ or ‘non or 
infrequent’. Participants were classified by genotype according to alleles of the rs1229984 
SNP, either ‘GG’ or ‘AA/AG’. CWP was defined as pain all over the body for more than 3 
months that interfered with activities. Associations between genotype, CWP and alcohol 
consumption were tested by logistic regression. Instrumental variable analysis was used to 
calculate the causal effect of weekly alcohol consumption on CWP. Persons with ‘GG’ 
genotype had an increased risk of CWP (odds ratio, OR 1.17, 99% confidence interval CI 
1.01-1.35) and were more likely to consume alcohol weekly (OR 1.76, 1.70-1.81) compared 
to those with ‘AA/AG’ genotype. Weekly consumption of alcohol was associated with 
reduced risk of CWP (OR 0.33, 0.31-0.35), but instrumental variable analysis did not show a 
causal effect of alcohol consumption on reducing CWP (OR 1.29, 0.96-1.74). An 
interpretation of observational population studies as showing a protective effect of alcohol on 
CWP is not supported. 
 
Keywords: alcohol, drinking, chronic widespread pain, epidemiology, Mendelian 
randomisation  
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INTRODUCTION 
A defining feature of fibromyalgia is chronic pain all over the body, or chronic widespread 
pain (CWP) [23,24]. One estimate of global fibromyalgia prevalence is 2.7% [20] but 
estimates can range from 1.1 to 6.4% depending on criteria used [11,22]. Meta-analyses have 
estimated CWP prevalence at 9.8% globally [1] and 14.2% within the UK [7]. Among 
lifestyle factors associated with fibromyalgia and CWP is alcohol consumption. One study 
among fibromyalgia patients found moderate alcohol consumption was associated with 
reduced symptom severity compared to abstention [13]. The authors suggested ethanol-
enhanced production of γ-Aminobutyric Acid (GABA) [12] as a mechanism for effects of 
alcohol in people with fibromyalgia, among whom studies have shown decreased levels of 
GABA [9]. Population studies have found CWP is less common among persons with 
moderate alcohol consumption, even among those who had not reduced drinking due to ill 
health [3]. In one study, those drinking 11 to 35 units a week were a third less likely to report 
CWP as those who had never drunk regularly, while among people with CWP, moderate 
alcohol consumption was associated with less disability [15]. 
There are limits to inferences that can be drawn from observational studies [8]. It is 
conceivable that alcohol has analgesic effects, and that is why moderate drinkers report less 
pain. However, these studies are prone to confounding and ‘reverse causation’. A confounded 
relationship would mean a third variable associated with alcohol consumption but is not its 
consequent, though it may be its antecedent, has an effect on pain.  ‘Reverse causation’ could 
mean that people reduce their alcohol intake because they have chronic pain. Both 
explanations would produce the associations described in previous studies.  
One study design that overcomes some of these problems is Mendelian randomisation [2]. 
Mendelian randomisation is particularly useful when a randomised trial is not feasible, as 
when studying effects of alcohol consumption. In this design, genetic variants strongly 
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associated with a particular behaviour, such as a single genetic base or single-nucleotide 
polymorphism (SNP), are chosen as proxy measures for the behaviour [14]. Their distribution 
throughout a population is assumed random, so their influence is assumed to be distributed 
randomly and not influenced by confounders. One SNP that affects alcohol consumption is 
rs1229984 on chromosome 4, in the gene ADH1B for alcohol dehydrogenase. The common 
variant of this SNP is the guanine (G) nucleotide, while a smaller number of people carry one 
or two copies of the adenine (A) allele (global minor allele frequency between 0.0628 and 
0.159 [19]). Among people with the rare variant, increased production of alcohol 
dehydrogenase converts ethanol to acetaldehyde more rapidly so unpleasant effects are 
experienced after consuming alcohol [4]. Because of ill effects of alcohol, people manifesting 
AA or AG at rs1229984 consume less. 
The current analysis aimed to examine the association of variants of the rs1229984 SNP with 
reporting of CWP in a large population sample from the UK, and to use the variants as an 
instrumental variable for estimating the causal effect of alcohol consumption on CWP. 
 
METHODS 
UK Biobank 
The UK Biobank recruited over 500,000 participants aged between 40 and 69 years from 
among patients registered at general medical practitioners within the UK National Health 
Service [21]. Around 9.2 million people were invited to take part in the study, making a 
participation rate of 5.5% [16]. Participants attended assessment centres across the UK where 
they completed by touchscreen electronic questionnaires that included questions on health 
and lifestyle. Physical measures and biological samples were also collected at assessment 
centre visits. The UK Biobank is overseen by the UK Biobank Ethics and Governance 
Council, and has received approval from appropriate ethics committees. 
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Pain questions 
Participants were asked by touchscreen questionnaire ‘In the last month have you 
experienced any of the following that interfered with your usual activities?’ They were 
provided with a list of  options to choose from: headache, facial pain, neck or shoulder pain, 
back pain, stomach or abdominal pain, hip pain, knee pain, pain all over the body, none of the 
above, prefer not to answer. Participants who chose ‘pain all over the body’ were not offered 
the option of choosing any other pain sites. For each pain selected or for ‘pain all over the 
body’, they were then asked if they had the pain for more than 3 months. Participants were 
classified as having CWP if they answered they had ‘pain all over the body’, and that they 
had experienced this for more than 3 months. This definition of CWP has been used in a 
number of previous studies [3,16,17] 
Alcohol questions 
Participants were also asked ‘About how often do you drink alcohol?’, and given a number of 
options from which to choose. If participants answered ‘once or twice a month’, ‘special 
occasions only’, or ‘never’ they were classified as ‘non or infrequent’ drinkers of alcohol for 
this analysis. If their answer was ‘once or twice a week’, ‘3 or 4 times a week’, or ‘daily’, 
they were classed as ‘weekly consumers’ of alcohol.  
Other chronic pain risk markers 
A number of other risk markers for CWP were collected at the assessment centre visit and 
used as adjusting factors: age at time of visit in whole number of years, BMI calculated from 
height and weight measured at visit, and Townsend Deprivation index derived from a 
participant’s postcode. The following were also collected by touchscreen questionnaire: 
employment (classified for this analysis as employed/self-employed, retired, unable to work 
because of sickness/disability, unemployed, or none of the above/other); smoking (never, 
tried once or twice, previous occasional smoker, previous smoking most days, current 
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occasional smoker, or current smoker most days); self-reported ethnic group (classed as white 
or non-white ethnic background for this analysis); university degree or not; measures of 
mood (ever felt miserable, often felt fed-up); and frequency of visits with friends and family 
(2 or more a week versus 1 or less). 
Genotyping information 
Genotyping information was available for UK Biobank participants. Variants of rs1229984 
were used as markers for exposure to alcohol consumption. This SNP lies in exon 3 of the 
ADH1B gene which codes for an alcohol dehydrogenase. The reference allele is guanine (G) 
and carriers of one or two copies of the adenine (A) allele have faster metabolism of alcohol. 
These people are more likely to have unpleasant effects from drinking and so drink less and 
are at lower risk for alcoholism [4]. For this analysis, participants were classed as either 
carrying the ‘GG’ or ‘AA/AG’ variants of rs1229984. Those with ‘AA’ and ‘AG’ variants 
were combined into one group because of the lower minor allele frequency for rs1229984 [4].  
Analysis 
Stata/SE 13.0 was used to examine associations between alcohol consumption, CWP, and 
genotype. First, the association between reporting CWP and variants of the rs1229984 SNP 
was examined. The percentage of those having CWP in each genotype (‘AA/AG’ and ‘GG’) 
was calculated. Logistic regression was used to calculate the odds ratio (OR) with 99% 
confidence interval (CI) for reporting CWP in those with the ‘GG’ genotype compared to 
those with ‘AA/AG’. Analyses were performed separately for males and females, and in 
those of self-reported white and non-white ethnicity. Analyses were stratified by gender and 
ethnicity since gender is associated with both CWP and alcohol consumption, and self-
reported ethnicity is associated with CWP and genotype. ORs adjusted for age, gender, and 
chronic pain risk markers, were calculated 
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In order to confirm the association of the rs1229984 SNP with alcohol consumption, the 
proportion of weekly consumers of alcohol and those not consuming or consuming 
infrequently was calculated for each genotype. Logistic regression was used to calculate ORs 
of weekly consumption of alcohol in those with the ‘GG’ genotype compared to those with 
‘AA/AG’. This was repeated separately for those of each gender, and for those of self-
reported white and non-white ethnicity. 
Next, the association between alcohol consumption and CWP in the population was 
confirmed. The percentage of those with CWP in consuming alcohol weekly, and in those not 
consuming or consuming infrequently was calculated. ORs for reporting of CWP in ‘weekly 
consumers’ compared to ‘non or infrequent’ consumers were calculated with 99% confidence 
intervals (CI) by logistic regression. Adjusted odds ratios (AORs) with 99% CIs were then 
calculated using logistic regression. Analyses were repeated in those of white and non-white 
ethnicity, and in both genders. 
Instrumental variable analysis by the inverse-variance weighting (ratio) method [5] was used 
to calculate the causal effect of weekly consumption of alcohol on CWP, using variants of the 
rs1229984 SNP as an instrumental variable and ‘non or infrequent’ as the reference category. 
In this method, the ratio of the coefficient of CWP regressed on genotype (adjusted for 
covariates) to the coefficient of alcohol regressed on genotype (also adjusted) gives the causal 
estimate of the effect of alcohol on CWP. The coefficients were obtained from logistic 
regression models, and odds ratios were obtained by exponentiation of the ratio of the 
coefficients. The standard error estimates for the risk ratios were adjusted for the observed 
correlation between CWP and alcohol consumption.  ORs with 99% CIs are reported overall 
and separately for each category of gender and ethnicity.  
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RESULTS 
Alcohol consumption information was available for 501,098 participants of whom 344,656 
(68.9%) reported consuming alcohol weekly. Pain information was available for 500,410 
participants of whom 7,130 (1.4%) reported CWP. Genotype was available for 486,321 
participants of whom 28,511 (5.9%) were ‘AA/AG’. The number of participants who had 
alcohol, pain, and genotype information available was 484,178. Characteristics of participants 
by genotype are given in Table 1. Those with ‘GG’ genotype tended to have higher BMI and 
greater deprivation than those of ‘AA/AG’ genotype, and were less likely to be of non-white 
ethnicity. There were also differences in employment status and number of those with a 
university degree. Differences in smoking behaviour and other characteristics were small. 
Genotype and CWP 
Participants of ‘GG’ genotype were slightly more likely to report CWP than those with 
‘AA/GG’ (Table 2) (1.4 vs. 1.2%, OR 1.17, 99% CI 1.01-1.35)). The estimate of effect did 
not exclude the null in the 99% CI after adjustment for other risk markers (aOR 1.14, 0.97-
1.33). Higher prevalence of CWP was also seen among those with the ‘GG’ genotype when 
looking separately at those of white ethnicity and non-white ethnicity (1.3 vs. 1.1%, OR 1.25, 
1.06-1.48, and 3.4 vs. 2.1%, OR 1.64, 1.24-2.20 respectively). The size of these effects were 
attenuated and failed to exclude the null from the 99% CI when adjusted for CWP risk 
markers. 
Genotype and alcohol consumption 
Among participants for whom information on alcohol consumption and genotype was 
available, there were differences in alcohol consumption among those of the ‘GG’ and 
‘AA/AG’ genotypes (Table 3). Among males, those of ‘GG’ genotype were more likely to 
consume alcohol weekly compared to those with ‘AA/AG’ (77.8 vs. 67.1%, OR 1.71, 1.63-
1.80, aOR 1.60, 1.52-1.69). Among females the same patterns were observed with 62.9% of 
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those of ‘GG’ genotype consuming alcohol weekly compared to 47.8% of those drinking 
none or infrequently (OR 1.85, 1.77-1.93, aOR 1.77, 1.69-1.86). The same pattern was 
observed in both those of white and non-white ethnicities, with a greater proportion among 
those of ‘GG’ genotype consuming alcohol weekly. 
Association between alcohol consumption and CWP in the population 
Participants who reported consuming alcohol weekly were less likely to report CWP 
compared to those drinking none or infrequently (Table 4, Figure 1) (0.9 vs 2.6%, OR 0.33, 
0.31-0.35, aOR 0.56, 0.53-0.61). This was observed among those of white and non-white 
ethnicity and in both genders. 
Causal effect of weekly alcohol consumption on risk of CWP 
The estimate of the causal effect of alcohol consumption on risk of CWP using instrumental 
variable analysis did not show a decreased risk with weekly consumption of alcohol (Table 
4, Figure 1) (OR 1.29, 0.96-1.74). Effect estimates were similar for males and females, and 
those of white and non-white ethnicity, ranging from ORs of 1.28 to 1.49, apart from among 
non-white males which showed a small decreased risk of OR 0.96. None of the effect 
estimates excluded the null in their 99% confidence intervals. 
 
DISCUSSION 
We did not find evidence for a protective effect of weekly alcohol consumption on the 
reporting of CWP. Those participants with a genetic predisposition to avoid alcohol were less 
likely to report CWP, not more. The results of the instrumental variable analysis suggest there 
could be a small harmful effect of alcohol on CWP. 
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The main strength of the study is that of the Mendelian randomisation method. To the extent 
that variants of the rs1229984 SNP are distributed randomly among the population, they are 
not confounded with other factors that may have an effect on the outcome. This method also 
deals with the problem of so-called ‘reverse causation’. While in traditional observational 
studies the direction of causality between two associated variables is difficult to ascertain, in 
our study, it is not possible that being less likely to report pain caused people to carry the A 
allele. Additional strengths of this study include its large sample size, the availability of a 
number of other CWP risk markers, and similar levels of alcohol consumption as found in 
other surveys in the UK population [6]. Also, the definition of CWP used (chronic pain all 
over the body that has interfered with activities and experienced for more than 3 months) 
gave prevalence estimates consistent with that of fibromyalgia, indicating that we were likely 
considering a phenotype at the same extreme end of the pain spectrum. 
 
There are however limitations to our study. One is that rare variants of the SNP may not be 
randomly distributed throughout the population. Carriers of the rs1229984 A allele are more 
likely to be of non-white ethnicity. In the sample studied here, ethnicity is itself associated 
with socio-demographic factors, and with the reporting of pain [16]. However, the observed 
associations between the SNP variant and CWP held when looking at those of self-reported 
white ethnic background alone. Furthermore, for our analysis all those of non-white ethnic 
background were included in the same category. This was not in order to make any inferences 
about this group of people, as we would expect it to be quite heterogeneous, but only 
included for completeness. Another limitation of the method is that the SNP used may have 
pleiotropic effects, that is, effects of the variants on CWP other than through their effects on 
alcohol consumption. In our instrumental variable analysis we dealt with this by adjusting for 
a number of common risk markers for CWP. This however makes the assumption that these 
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risk markers were not on the casual pathway between alcohol consumption and CWP. For 
some of these covariates, for example gender and ethnicity, this was a reasonable assumption. 
It is possible however, that some of these covariates are pathway variables mediating the 
effect of alcohol on CWP in which case our estimate of the effect could be biased [5]. The 
direction of this potential bias could mean we have underestimated the effect of alcohol on 
pain so would not alter the conclusion that alcohol does not have a positive effect on pain. 
 
Previous studies have found that CWP reporting was greater in non-drinkers compared to 
those drinking alcohol moderately [3,15], and the current study confirmed that association. 
The current study also concluded that, using variants of SNPs as a marker for alcohol 
consumption, alcohol consumption does not prevent CWP. While previous studies were 
observational and could only make a comment about associations between alcohol 
consumption and CWP, the current study used a method that allows an estimate of the causal 
effect of alcohol on CWP. We can conclude that the previous results were not due to 
moderate alcohol consumption causing people to have less pain. The results of those 
observational studies could instead be due to the effect of having pain on alcohol 
consumption, that is, people with pain being more likely to reduce their consumption. Our 
study did not have the power to examine small effects of alcohol consumption on CWP, and 
we cannot rule out the null hypothesis that there was no effect. However, the direction of 
effect means it is possible that alcohol consumption has a small harmful effect on CWP. It 
may be that at the population level, people with CWP reduce their consumption of alcohol 
because of the harmful effect on their symptoms. 
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In this study, the best estimate of the effect of weekly alcohol consumption on risk of CWP 
was small (risk ratio of about 1.3). For a condition with a low prevalence (1.5%), this 
represents an absolute increase in risk of about 4 people per thousand. A randomised trial 
designed to assess this size of difference at 5% significance level with 90% power, and 100% 
treatment compliance, would require a sample size of over 67,000 participants.  However, 
this estimate effect of alcohol on CWP has been adjusted for covariates. Some of these are 
among possible consequences of drinking alcohol (higher BMI, worse mood, lower levels of 
education) and could be regarded as potential mediators of its influence on CWP. In that case, 
it is possible that the true effect is larger than this. It is also possible that these covariates are 
colliders, consequences of both alcohol consumption and CWP, which would also influence 
the estimate of effect. 
 
This results of this and previous studies leave some unanswered questions. Here, we 
estimated a small negative effect of alcohol consumption on CWP but could not rule out 
sampling error. If drinking alcohol does increase the risk of CWP we would have to consider 
by what mechanism. A general question for epidemiological researchers is how such a strong 
relationship as seen in the population between moderate levels of alcohol consumption and 
decreased CWP might come about given that that alcohol consumption does not lower the 
risk of CWP. The population-level effect may be behavioural, that is to say people who are at 
higher risk of CWP actively change their behaviour to avoid drinking. Possible reasons for 
avoidance of alcohol among patients with CWP are the use of medications for which alcohol 
consumption is proscribed, or that alcohol may be exacerbating symptoms, but this is an area 
for future research. 
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In conclusion, this study found those participants that had a genetic predisposition to avoid 
alcohol consumption reported less CWP not more. An instrumental variable analysis showed 
that weekly alcohol consumption does not cause the risk of CWP to be decreased. The 
interpretation of observational population studies as showing a protective effective of alcohol 
against pain is not supported. 
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Table 1 Participant characteristics by genotype 
 AA/AG GG OR (99% CI) Difference (99% CI) n 
      
Age, mean (SD), years 56.1 (8.16) 56.6 (8.09) - 0.44 (0.32-0.57) 486,306 
      
Gender, Female (%) 15,412 (54.1) 248,218 (54.2) 1.01 (0.98-1.04) - 486,306 
      
Ethnicity, Non-white (%) 4,464 (15.6) 21,190 (4.7) 0.26 (0.25-0.27) - 484,007 
      
BMI, mean (SD) 27.0 (4.64) 27.4 (4.80) - 0.48 (0.40-0.55) 484,335 
      
Townsend Index, mean (SD) -1.16 (3.175) -1.32 (3.083) - -0.16 (-0.21- -0.11) 485,708 
      
Employment 
status 
Employed or self-employed 16,767 (59.4) 261,454 (57.4) 1 [Ref] - 
483,819 
Retired 8.703 (30.8) 153,272 (33.6) 1.13 (1.09-1.17) - 
Unable to work 801 (2.8) 15,223 (3.3) 1.22 (1.11-1.34) - 
Unemployed 548 (1.9) 7,406 (1.6) 0.87 (0.77-0.97) - 
None of above 1425 (5.1) 18.220 (4.0) 0.82 (0.76-0.88) - 
      
Smoking 
Never 11,547 (40.8) 182,851 (40.1) 1 [Ref] - 
483,805 
Tried once or twice 4,175 (14.8) 66,273 (14.6) 1.00 (0.96-1.05) - 
Previous, occasional 3,230 (11.4) 52,223 (11.5) 1.02 (0.97-1.08) - 
Previous, most days 6,389 (22.6) 106,055 (23.3) 1.05 (1.00-1.09) - 
Current, occasionally 857 (3.0) 12,373 (2.7) 0.91 (0.83-1.00) - 
Current, most days 2,098 (7.4) 35,734 (7.8) 1.08 (1.01-1.15) - 
      
University degree, Yes (%) 10,836 (38.7) 146,423 (32.4) 0.76 (0.73-0.78) - 480,062 
      
Miserable, Yes (%) 11,570 (41.7) 192,214, (42.8) 1.05 (1.02-1.08) - 476,645 
      
Fed up, Yes (%) 10,711 (38.81) 181,903 (40.7) 1.08 (1.05-1.12) - 474,587 
      
Frequent family/friend visits, Yes (%) 11,243 (40.0) 193,367 (42.6) 1.11 (1.08-1.15) - 482,210 
      
OR, odds ratio or multinomial odds ratio; CI, confidence interval; n, number of participants used for calculation; BMI, body mass index 
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Table 2 Association of CWP with variants of rs1229984 
Ethnicity Gender Variant No CWP CWP OR (99% CI) n AOR (99% CI) n 
         
All 
All 
AA/AG 27973 (98.8) 344 (1.2) 1 [Ref] 
484,575 
1 [Ref] 
454,400 
GG 449807 (98.6) 6451 (1.4) 1.17 (1.01-1.35) 1.14 (0.97-1.33) 
        
Male 
AA/AG 12876 (99.0) 125 (1.0) 1 [Ref] 
221,873 
1 [Ref] 
207,436 
GG 206517 (98.9) 2355 (1.1) 1.17 (0.93-1.49) 1.11 (0.86-1.44) 
        
Female 
AA/AG 15097 (98.6) 219 (1.4) 1 [Ref] 
262,702 
1 [Ref] 
246,964 
GG 243290 (98.3) 4096 (1.7) 1.16 (0.97-1.39) 1.15 (0.95-1.40) 
         
White 
All 
AA/AG 23511 (98.9) 250 (1.1) 1 [Ref] 
457,553 
1 [Ref] 
432,962 
GG 428084 (98.7) 5708 (1.3) 1.25 (1.06-1.48) 1.14 (0.95-1.36) 
        
Male 
AA/AG 11009 (99.2) 90 (0.8) 1 [Ref] 
209,237 
1 [Ref] 
197,702 
GG 196027 (98.9) 2111 (1.1) 1.32 (1.00-1.74) 1.14 (0.85-1.54) 
        
Female 
AA/AG 12502 (98.7) 160 (1.3) 1 [Ref] 
248,316 
1 [Ref] 
235,260 
GG 232057 (98.5) 3597 (1.5) 1.21 (0.98-1.49) 1.14 (0.91-1.42) 
         
Non-white 
All 
AA/AG 4317 (97.9) 92 (2.1) 1 [Ref] 
25,390 
1 [Ref] 
21,438 
GG 20269 (96.6) 712 (3.4) 1.65 (1.24-2.20) 1.16 (0.84-1.61) 
        
Male 
AA/AG 1801 (98.2) 34 (1.9) 1 [Ref] 
11,713 
1 [Ref] 
9,734 
GG 9648 (97.7) 230 (2.3) 1.26 (0.78-2.04) 0.99 (0.56-1.74) 
        
Female 
AA/AG 2516 (97.7) 58 (2.3) 1 [Ref] 
13,677 
1 [Ref] 
11,704 
GG 10621 (95.7) 482 (4.3) 1.97 (1.37-2.83) 1.23 (0.82-1.85) 
         
CWP, chronic widespread pain; OR, odds ratio; CI, confidence interval; n, number of participants used for individual calculation; AOR, 
adjusted odds ratio 
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Table 3 Association of alcohol consumption with variants of rs1229984 
Ethnicity Gender Variant Non or infrequent Weekly consumption OR (99% CI) n AOR (99% CI) n 
         
All 
All 
AA/AG 12304 (43.3) 16097 (56.7) 1 [Ref] 
485,227 
1 [Ref] 
454,758 
GG 138480 (30.3) 318346 (69.7) 1.76 (1.70-1.81) 1.69 (1.63-1.76) 
        
Male 
AA/AG 4290 (32.9) 8753 (67.1) 1 [Ref] 
222,143 
1 [Ref] 
207,549 
GG 46519 (22.3) 162581 (77.8) 1.71 (1.63-1.80) 1.60 (1.52-1.69) 
        
Female 
AA/AG 8014 (52.2) 7344 (47.8) 1 [Ref] 
263,084 
1 [Ref] 
247,209 
GG 91961 (37.1) 155765 (62.9) 1.85 (1.77-1.93) 1.77 (1.69-1.86) 
         
White 
All 
AA/AG 9031 (38.0) 14762 (62.0) 1 [Ref] 
458,029 
1 [Ref] 
433,273 
GG 124252 (28.6) 309984 (71.4) 1.53 (1.47-1.58) 1.69 (1.63-1.76) 
        
Male 
AA/AG 3087 (27.8) 8029 (72.2) 1 [Ref] 
209,414 
1 [Ref] 
197,798 
GG 40760 (20.6) 157538 (79.4) 1.49 (1.40-1.57) 1.60 (1.51-1.70) 
        
Female 
AA/AG 5944 (46.9) 6733 (53.1) 1 [Ref] 
248,615 
1 [Ref] 
235,475 
GG 83492 (35.4) 152446 (64.6) 1.61 (1.53-1.69) 1.76 (1.68-1.85) 
         
Non-white 
All 
AA/AG 3189 (71.6) 1265 (28.4) 1 [Ref] 
25,533 
1 [Ref] 
21,485 
GG 13614 (64.6) 7465 (35.4) 1.38 (1.26-1.52) 1.65 (1.48-1.84) 
        
Male 
AA/AG 1171 (63.1) 685 (36.9) 1 [Ref] 
11,786 
1 [Ref] 
9,751 
GG 5456 (54.9) 4474 (45.1) 1.40 (1.22-1.60) 1.61 (1.38-1.88) 
        
Female 
AA/AG 2018 (77.7) 580 (22.3) 1 [Ref] 
13,747 
1 [Ref] 
11,734 
GG 8158 (73.2) 2991 (26.8) 1.28 (1.11-1.46) 1.70 (1.45-1.98) 
         
OR, odds ratio; CI, confidence interval; n, number of participants used for individual calculation; AOR, adjusted odds ratio 
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Table 4 Association of weekly alcohol consumption and CWP, and causal effect of weekly consumption on CWP 
 
     Association in the population Estimated causal effect 
Ethnicity Gender Consumption No CWP CWP OR (99% CI) n AOR (99% CI) n OR (99% CI) n 
           
All 
All 
None 151739 (97.4) 4077 (2.6) 1 [Ref] 
499,988 
1 [Ref] 
465,150 
1 [Ref] 
454,178 
Weekly 341132 (99.1) 3040 (0.9) 0.33 (0.31-0.35) 0.56 (0.53-0.61) 1.29 (0.96-1.74) 
          
Male 
None 51048 (97.8) 1150 (2.2) 1 [Ref] 
227,901 
1 [Ref] 
211,352 
1 [Ref] 
207,324 
Weekly 174272 (99.2) 1431 (0.8) 0.36 (0.33-0.40) 0.61 (0.54-0.69) 1.28 (0.73-2.23) 
          
Female 
None 100691 (97.2) 2927 (2.8) 1 [Ref] 
272,087 
1 [Ref] 
253,798 
1 [Ref] 
262,507 
Weekly 166860 (99.0) 1609 (1.0) 0.33 (0.31-0.36) 0.54 (0.49-0.59) 1.29 (0.91-1.82) 
           
White 
All 
None 134234 (97.6) 3327 (2.4) 1 [Ref] 
471,633 
1 [Ref] 
442,840 
1 [Ref] 
432,779 
Weekly 331181 (99.1) 2891 (0.9) 0.35 (0.33-0.38) 0.57 (0.53-0.62) 1.31 (0.93-1.84) 
          
Male 
None 44106 (98.0) 923 (2.0) 1 [Ref] 
214,785 
1 [Ref] 
201,349 
1 [Ref] 
197,612 
Weekly 168396 (99.2) 1360 (0.8) 0.39 (0.35-0.43) 0.63 (0.55-0.71) 1.37 (0.73-2.57) 
          
Female 
None 90128 (97.4) 2404 (2.6) 1 [Ref] 
256,848 
1 [Ref] 
241,491 
1 [Ref] 
235,167 
Weekly 162785 (99.1) 1531 (0.9) 0.35 (0.32-0.38) 0.54 (0.49-0.59) 1.28 (0.86-1.89) 
           
Non-
white 
All 
None 16828 (95.9) 721 (4.1) 1 [Ref] 
26,657 
1 [Ref] 
22,310 
1 [Ref] 
21,399 
Weekly 8968 (98.5) 140 (1.5) 0.36 (0.29-0.46) 0.52 (0.39-0.68) 1.35 (0.69-2.63) 
          
Male 
None 6617 (96.9) 214 (3.1) 1 [Ref] 
12,155 
1 [Ref] 
10,003 
1 [Ref] 
9,712 
Weekly 5257 (98.7) 67 (1.3) 0.39 (0.27-0.57) 0.49 (0.32-0.75) 0.96 (0.30-3.13) 
          
Female 
None 10211 (95.3) 507 (4.7) 1 [Ref] 
14,502 
1 [Ref] 
12,307 
1 [Ref] 
11,687 
Weekly 3711 (98.1) 73 (1.9) 0.40 (0.29-0.55) 0.52 (0.36-0.75) 1.49 (0.68-3.28) 
           
CWP, chronic widespread pain; OR, odds ratio; CI, confidence interval; n, number of participants used for individual calculation; AOR, adjusted odds ratio 
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